

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER

RETIREMENT OF CHIEF FINANCIAL OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Ronald Hao Xi Ede (“**Mr. Ede**”) will retire from his position as the chief financial officer of the Company (the “**CFO**”), with effect from February 5, 2024. Mr. Ede will continue to serve on the Board as an executive Director, participating in the Board’s strategic and business decisions, as well as serve as the managing partner of the Company’s funds and take full charge of the Company’s fund management. Mr. Ede joined the Company in 2017 and during his CFO tenure, has made significant contributions to the Company’s strategy planning, corporate governance, financial management and business development. He successfully led the listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and a series of post-listing fund raising activities, which have laid a solid foundation for the Company’s continuous growth.

Mr. Ede has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board is pleased to announce that Ms. Fei You (“**Ms. You**”) has been appointed as the new CFO, with effect from February 5, 2024. Ms. You is responsible for the financial management and capital market activities of the Company, etc. Ms. You has over 20 years of professional experience in financial management, strategic investment and financing. Before joining the Company, she served as the chief financial officer of Jinxin Fertility Group Ltd. (a company listed on the Stock Exchange with stock code: 1951) and has successfully led its listing on the Main Board of the Stock Exchange. Prior to that, she had served in various managerial positions of 3SBio Inc. (a company listed on the Stock Exchange with stock code: 1530) and KPMG, etc.

The Board would like to take this opportunity to express its sincere gratitude for the dedication and contribution of Mr. Ede during his entire tenure as the CFO, and looks forward to continue to working with Mr. Ede on the Board. At the same time, the Board warmly welcomes Ms. You as the new CFO, and looks forward to working with her on the journey to pursue the mission of the Company in ‘developing high-quality biopharmaceuticals that are affordable to ordinary people’ and the vision of the Company in ‘being one of the world’s leading biopharmaceutical companies’.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
February 5, 2024

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.